RMD

Business profile & competitive position

ResMed Inc. is classified in the Healthcare sector, specifically the Medical – Instruments & Supplies industry. Its core business is cloud-connected medical devices and software for sleep and breathing health: CPAP, APAP, bilevel and ventilation devices, masks and accessories, sleep diagnostics, dental devices, plus connected-care software. It also runs a Residential Care Software segment that serves home medical equipment, home health, hospice, skilled nursing and senior living providers. Products are sold in more than 140 countries through subsidiaries and independent distributors, and as of the filing the company listed roughly 35 million cloud-connected devices feeding its AirView remote-monitoring platform and over 12 million patients registered on its myAir patient-engagement app.

The financial footprint suggests a business with meaningful recurring elements and a durable installed base. Net margin is 26.9% and return on equity is 23.9%. Margins in the mid-to-high twenties are material for a medical-device supplier and usually point to pricing power, repeat purchases of masks and accessories, and a platform that is hard to displace once a patient is onboarded. The beta of 0.75 also indicates the stock has historically moved less violently than the broad market, which fits a company whose revenue is partly subscription-like and tied to long-term therapy adherence rather than discretionary spending. That said, the moat is not absolute: regulators, reimbursement agencies and rapid shifts in treatment paradigms can reshape demand quickly, so the economic returns should be read as evidence of current strength rather than a guarantee of future dominance.

Financial posture

ResMed currently carries a market capitalization of $34.0 billion and trades at a price-to-earnings ratio of 22.5. That multiple, paired with a net margin of 26.9% and an ROE of 23.9%, frames the company as a profitable, large-cap healthcare name rather than a speculative growth stock. A 23.9% ROE implies management has been effective at generating shareholder returns from the equity base, while a 26.9% net margin shows the business retains a healthy slice of each revenue dollar after all expenses.

At the current price of $234.6, the stock is trading above its 50-day exponential moving average of $222.34, and the relative strength index sits at 65.8. An RSI near 65 is approaching the common 70 overbought threshold but is not yet there. The beta of 0.75 reinforces the lower-volatility profile typical of large healthcare equipment names. Overall, the posture is one of a mature, cash-generative business priced at a market-level to modestly premium earnings multiple, supported by strong margins and returns but without the high-growth valuation often attached to earlier-stage medical technology names.

Strategic priorities & outlook

ResMed’s most recent 10-K filing outlines a clear strategic focus on sleep apnea, COPD and connected home-based healthcare. The company intends to grow and differentiate its core sleep apnea portfolio by integrating artificial intelligence and machine learning, simplifying care pathways, and expanding home diagnostics including the NightOwl platform and the recently acquired VirtuOx IDTF business. Patient and physician education is another stated priority, aimed at expanding awareness of sleep apnea, COPD and related comorbidities.

Management also wants to push into broader sleep and breathing health adjacencies, including COPD, neuromuscular disease and restless legs syndrome through the Noctrix acquisition. The digital-health ecosystem is central: AirView and myAir are positioned as the connective tissue that links devices, providers and patients at home. Financially, the Sleep and Breathing Health segment is the dominant contributor, with devices producing roughly 51% of net revenue in fiscal 2026, masks, diagnostics and accessories contributing about 37%, and software adding around 12%.

A notable portfolio move came in June 2026, when ResMed agreed to sell its MatrixCare business for $490 million in cash. The deal is expected to close in the first quarter of fiscal 2027 and is described as a way to sharpen focus on core sleep, breathing and connected home-based healthcare. With approximately 11,370 employees, the company is positioning itself around cloud-connected device hardware, recurring mask and accessory sales, and platform-driven patient adherence.

Macro & geopolitical exposure

As a Healthcare / Medical – Instruments & Supplies name, ResMed is exposed to the usual industry-wide forces rather than a single commodity cycle. Regulatory risk is central: FDA clearances, changes to reimbursement schedules under CMS or private payers, and product-safety recalls can move demand and margins materially. The U.S. durable medical equipment reimbursement environment has historically been a key swing factor for CPAP and ventilation products.

Trade policy and supply-chain geography matter as well. Medical devices rely on specialized chips, motors, sensors and plastics, and a meaningful portion of the industry’s hardware supply chain is global. Tariffs or export restrictions can raise costs or delay shipments. Currency also plays a role because more than 140 countries contribute to the revenue mix, so dollar strength or weakness directly affects translated results. Finally, the recent narrative around GLP-1 weight-loss therapies illustrates how external treatment trends can reshape a respiratory-device market; even if ResMed currently frames GLP-1 users as incremental demand drivers, any long-term change in sleep apnea prevalence or diagnosis patterns could alter the addressable market.

Recent developments

The most recent headlines give a concise picture of what the market is watching. On October 11, 2026, Seeking Alpha included ResMed in its “Top 50 High-Quality Dividend Growth Stocks For October 2026,” and on the same day defenseworld.net reported that the CEO sold stock worth $1,129,613.03. Insider sales by a chief executive are a routine disclosure item, but the exact dollar figure and timing ahead of earnings are worth noting. Earlier, on October 1, 2026, GlobeNewswire confirmed that ResMed will report first quarter fiscal 2027 earnings on October 29, 2026, after the market close. The consensus EPS estimate heading into that report is $2.68.

On September 22, 2026, defenseworld.net published a headline saying ResMed is “Targeting 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand.” That statement ties back to the strategic narrative in the 10-K: the company is trying to frame GLP-1-driven weight loss not as a threat to CPAP demand but as a catalyst that brings more diagnosed patients into therapy. Between the earnings calendar, the insider sale disclosure, the dividend-growth mention and the GLP-1 demand story, the upcoming October 29 report will likely need to reconcile actual revenue performance against management’s double-digit EPS growth ambition.

Earnings behavior & post-earnings drift

ResMed has beaten earnings expectations in 7 of the last 8 reported quarters, an 88% beat rate, with an average earnings surprise of 3%. The market has historically anticipated strong results, which is why the reported beat rate is high while the surprise magnitude is modest. The average 5-day price move following earnings across those same eight quarters is just 0.24%, classified as flat. In other words, beating estimates has rarely produced a sustained directional drift.

The last four quarters illustrate that pattern clearly. On August 6, 2026, ResMed reported EPS of $2.95 versus an estimate of $2.89, a 2.1% beat, yet the stock fell 5.06% the next day and only recovered to a 1.57% five-day gain. On April 30, 2026, EPS of $2.86 beat the $2.80 estimate by 2.1%, but the stock dropped 4.11% the next day and declined 3.24% over the following five days. January 29, 2026, was the exception: EPS of $2.81 beat the $2.74 estimate by 2.6%, and the stock rose 0.27% the next day and 3.66% over the next five sessions. Going back to October 30, 2025, EPS of $2.55 beat the $2.51 estimate by 1.6%, but the next-day move was -2.13% and the five-day drift was -1.03%. The consistency of positive earnings surprises alongside mixed post-event price action suggests the market’s real expectation often runs ahead of the published consensus.

For a deeper dive into how institutional analysts are modeling ResMed’s path through the October 29 earnings report and the evolving GLP-1 landscape, explore the full institutional verdict on the ticker. It consolidates sell-side ratings, estimate revisions, and contextualizes whether the current valuation and earnings trajectory align with the broader market narrative.